Electra Therapeutics, Inc.
No SEC Form 4 filings for $ETRA in the last 30 days.
See all $ETRA insider activity →Electra Therapeutics (ETRA) plans a $325 million IPO on Nasdaq, offering 21.7 million shares at $14-$16 each. Led by Jefferies, TD Cowen, Evercore ISI, and Cantor, the deal signals strong institutional interest. Pricing is expected soon, with final price indicating market demand.
Electra Therapeutics aims for a $977.6M valuation in its U.S. IPO, offering 21.67M shares at $14-$16 each, raising up to $346.7M. The biotech company develops therapies for immunological diseases and cancer, with proceeds funding clinical trials. It plans to list on Nasdaq as 'ETRA'.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ETRA (Electra Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
New IPO terms provide a fresh pricing window for investors.
The IPO filing introduces a new tradable biotech with significant capital raise, likely generating buying interest.
AlphAI scores every news story that mentions ETRA with an AI model for sentiment and relevance, and aggregates insider trades from Electra Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Electra Therapeutics (ETRA) plans a $325 million IPO on Nasdaq, offering 21.7 million shares at $14-$16 each. Led by Jefferies, TD Cowen, Evercore ISI, and Cantor, the deal signals strong institutional interest. Pricing is expected soon, with final price indicating market demand.
2 min readElectra Therapeutics aims for a $977.6M valuation in its U.S. IPO, offering 21.67M shares at $14-$16 each, raising up to $346.7M. The biotech company develops therapies for immunological diseases and cancer, with proceeds funding clinical trials. It plans to list on Nasdaq as 'ETRA'.
2 min read
